

# Furanocoumarin metabolites as dietary biomarkers of grapefruit consumption

<b>Submission date</b> 07/02/2014	<b>Recruitment status</b> No longer recruiting	<input type="checkbox"/> Prospectively registered <input type="checkbox"/> Protocol
<b>Registration date</b> 13/05/2014	<b>Overall study status</b> Completed	<input type="checkbox"/> Statistical analysis plan <input type="checkbox"/> Results
<b>Last Edited</b> 13/05/2014	<b>Condition category</b> Other	<input type="checkbox"/> Individual participant data <input type="checkbox"/> Record updated in last year

## Plain English summary of protocol

### Background and study aims

Grapefruit contains high amounts of furanocoumarins, a group of compounds that are known to reduce the activity of intestinal enzymes. As a result, grapefruit juice can interact with a variety of drugs that are taken orally. The aim of this study is to find out whether the breakdown products of furanocoumarin can be used as markers of grapefruit juice consumption.

### Who can participate?

Healthy men aged 20-35 years.

### What does the study involve?

Participants will be randomly allocated to drink 250 mL of either orange, lemon or grapefruit juice at dinner time. There will then be a 7-day break in which participants are requested to avoid consuming citric-based products. Participants will then repeat this process twice with the second and third juices. Urine samples will be collected the day before the first intervention and in the morning following each intervention.

### What are the possible benefits and risks of participating?

The study was conducted according to the Declaration of Helsinki of the World Medical Association. The study was explained to subjects through verbal and written instructions, and written informed consent was obtained before participation.

### Where is the study run from?

This study involved the Department of Nutrition and Food Science of the University of Barcelona (Spain).

### When is the study starting and how long is it expected to run for?

This study will take place between May 2013 and March 2014.

### Who is funding the study?

This study is supported by CIBERobn.

Who is the main contact?  
Dr Rosa Lamuela-Raventós  
lamuela@ub.edu

## Contact information

**Type(s)**  
Scientific

**Contact name**  
Dr Rosa Lamuela-Raventós

**Contact details**  
Nutrition and Food Science Department  
School of Pharmacy  
University of Barcelona  
Av. Joan XXIII, s/n  
Barcelona  
Spain  
08028  
+34 (0) 934 034 843  
lamuela@ub.edu

## Additional identifiers

**Protocol serial number**  
N/A

## Study information

**Scientific Title**  
Targeted metabolomics approach for the determination of furanocoumarin metabolites in urine after grapefruit juice consumption

**Study objectives**  
Grapefruit contains considerable amounts of furanocoumarins, a family of compounds which are known to strongly inhibit intestinal cytochrome P450 (CYP) enzymes, namely CYP3A4. As a result, grapefruit juice can interact with a variety of orally administered drugs by increasing their bioavailability. This study aims to study the potential of furanocoumarin metabolites as specific biomarkers of grapefruit juice consumption.

**Ethics approval required**  
Old ethics approval format

**Ethics approval(s)**  
Ethics Committee of Clinical Investigation of the University of Barcelona (Spain), 18/12/2014, ref: IRB00003099

**Study design**

Open controlled clinical trial

**Primary study design**

Interventional

**Study type(s)**

Other

**Health condition(s) or problem(s) studied**

Concentration of furanocoumarin metabolites in urine

**Interventions**

Participants are randomly assigned following simple randomization procedures (computerized random numbers) to one of three treatment groups. The study is a randomized crossover feeding trial. Participants will cross over and undergo all three of the interventions.

Intervention 1: Administration of 250 mL orange juice.

Intervention 2: Administration of 250 mL lemon juice.

Intervention 3: Administration of 250 mL grapefruit juice

Before each intervention, participants will follow a 7-day washout period, avoiding consuming citric or citric-based products

**Intervention Type**

Other

**Phase**

Not Applicable

**Primary outcome(s)**

Furanocoumarin metabolites will be identified through liquid chromatography coupled to Orbitrap mass spectrometry. Concentrations of furanocoumarins will be determined by liquid chromatography coupled to tandem mass spectrometry (LCMS/MS). These determinations will be carried out in first morning urine samples collected the day before the first intervention and in the morning following each intervention.

**Key secondary outcome(s)**

N/A

**Completion date**

01/04/2014

**Eligibility**

**Key inclusion criteria**

Healthy adult males aged 20-35 years

**Participant type(s)**

Patient

**Healthy volunteers allowed**

No

**Age group**

Adult

**Sex**

Male

**Key exclusion criteria**

1. Previous history of cardiovascular disease (ischemic heart disease - angina or recent or old myocardial infarction, cerebral vascular accident, or peripheral vascular disease)
2. Homeostatic disorders
3. Any several chronic diseases
4. Hypertension or dyslipidemia
5. Smoking subjects
6. Alcoholism
7. Other toxic abuse

**Date of first enrolment**

01/05/2013

**Date of final enrolment**

01/04/2014

**Locations****Countries of recruitment**

Spain

**Study participating centre**

**Nutrition and Food Science Department**

Barcelona

Spain

08028

**Sponsor information****Organisation**

Centros de Investigación Biomédica en Red Fisiopatología de la Obesidad y la Nutrición (CIBERObn) (Spain)

**ROR**

<https://ror.org/02s65tk16>

# Funder(s)

## Funder type

Research organisation

## Funder Name

Centros de Investigación Biomédica en Red Fisiopatología de la Obesidad y la Nutrición (Centers of Biomedical Research Network Pathophysiology of Obesity and Nutrition) (CIBERObn) (Spain)

# Results and Publications

## Individual participant data (IPD) sharing plan

### IPD sharing plan summary

Not provided at time of registration